Approved Study Database

Ref. No. Scientific Title Principal investigator
2021.634 Gut microbiome and metabolites in Non-alcoholic fatty liver diseases Prof. WONG Vincent
黃煒燊
2022.255 Prognostic implication of baseline and changes in liver stiffness measurement and the FibroScan-aspartate aminotransferase (FAST), Agile 3+ and Agile 4 scores in patients with non-alcoholic fatty liver disease: A retrospective cohort study Dr. WONG Vincent
黃煒燊
2022.622 A Phase IIb/III Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis Prof. WONG Vincent
黃煒燊
2023.436 Monitoring changes in hepatic steatosis during a lifestyle intervention programme in patients with non-alcoholic fatty liver disease using the novel continuous controlled attenuation parameter versus MRI proton density fat fraction Dr. WONG Vincent
黃煒燊
2021.606 Viral Load and Hepatocellular Carcinoma Risk in Chronic Hepatitis B: Time to Consider Extended Treatment Indications Dr. WONG Vincent
黃煒燊
2022.208 Clinical and prognostic significance of intrahepatic fibroblast activation protein expression in patients with non-alcoholic fatty liver disease Dr. WONG Vincent
黃煒燊
2023.471 Validation and refinement of serum multi-OMIC signature for identifying liver fibrosis and metabolic dysfunction-associated steatohepatitis in the Asian population Dr. WONG Vincent
黃煒燊
2018.236 Prevalence and severity of chronic liver diseases among patients with psychiatric illness: A cross-sectional study using transient elastography Dr. WONG Vincent
黃煒燊
2019.136 Characterization of biology of nonalcoholic fatty liver disease by single-cell RNA sequencing Dr. WONG Vincent
黃煒燊
2018.230 Incidence of liver-related events among patients with psychiatric illness: A retrospective cohort study Dr. WONG Vincent
黃煒燊
2020.304 SGLT2 inhibitors and liver-related outcomes in patients with type 2 diabetes mellitus: A territory-wide retrospective cohort study Dr. WONG Vincent
黃煒燊
2019.139 Identification of fatty liver with advanced fibrosis in patients with type 2 diabetes using simple fibrosis scores and electronic reminder messages: A randomized controlled trial Dr. WONG Vincent
黃煒燊
2017.422 A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis Prof. WONG Vincent W.S.
黃偉燊
2003.338 A Study on Nonalcoholic Steatohepatitis (NASH) in Hong Kong Prof. WONG Vincent W.S.
2017.511 Biomarkers study on biological samples from NAFLD and NASH patients from the biobank at the Chinese University of Hong Kong Dr. WONG Vincent Wai Sun
黃煒燊
2017.166 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) Prof. WONG Vincent Wai Sun
黃煒燊
2014.586 CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis Prof. WONG Vincent Wai Sun
2017.001 Optimizing varices screening in cirrhotic patients with well-controlled chronic viral hepatitis: A prospective cohort study with transient elastography and multiparametric magnetic resonance imaging Dr. WONG Vincent Wai Sun
黃煒燊
2017.257 Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) Prof. WONG Vincent Wai Sun
黃煒燊
2016.606 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH) Prof. WONG Vincent Wai Sun
黃煒燊
2017.258 AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis Prof. WONG Vincent Wai Sun
黃煒燊
2016.698 Non-invasive diagnosis and prognosis of nonalcoholic steatohepatitis and liver fibrosis: A clinicopathological study of metabolite, lipid, and protein biomarkers Dr. WONG Vincent Wai Sun
黃煒燊
2017.611 A 12-week randomized, patient and investigator blinded, placebo-controlled, parallel group study to investigate the efficacy of LIK066 in obese patients with non-alcoholic steatohepatitis (NASH) Prof. WONG Vincent Wai Sun
黃煒燊
2006.439 Collection of Blood and Liver Biopsy Samples for Liver Fibrosis Study Dr. WONG Vincent Wai Sun
2018.151 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) Prof. WONG Vincent Wai Sun
黃煒燊
2020.306 Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4) Prof. WONG Vincent Wai Sun
黃煒燊
2019.415 A Phase 2b, Multicenter, Double-blind, Active Controlled, Randomized Study to Investigate the Efficacy and Safety of different combination regimens including JNJ-73763989 and/or JNJ-56136379 for the treatment of Chronic Hepatitis B Virus Infection Prof. WONG Vincent Wai Sun
2020.303 A Phase 2, Randomized, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging, Dose-finding, Parallel Group Study to Assess Efficacy and Safety of PF 06865571 (DGAT2i) Alone and When Coadministered with PF-05221304 (ACCi) in Adult Participants with Biopsy-confirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 or 3 Prof. WONG Vincent Wai Sun
黃煒燊
2018.301 A Registry Study to Assess Patient Reported Outcomes (PRO’s) in Patients with Liver Diseases (CLD-PRO Global Registry Study) Prof. WONG Vincent Wai Sun
黃煒燊
2020.602 A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis Prof. WONG Vincent Wai Sun
黃煒燊教授
2023.183 A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele Prof. WONG Vincent Wai Sun
2024.124 Assessing the safety of discontinuing non-selective beta-blockers in cirrhotic patients with managed primary aetiological factors according to Baveno VII consensus Professor Wong Vincent Wai Sun
黃煒燊
2023.249 A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis Prof. WONG Vincent Wai Sun
2023.182 A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of HTD1801 in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis who Have Type 2 Diabetes or Pre-Diabetes (The CENTRICITY Study) Prof. WONG Vincent Wai Sun
2021.189 Multicenter, double-blind, parallel-group, randomised, 48 weeks, dose-ranging, placebo-controlled phase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of BI 456906 in patients with non-alcoholic steatohepatitis (NASH) and fibrosis Prof. WONG Vincent Wai Sun
黃煒燊教授
2024.292 A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis Prof. WONG Vincent Wai Sun
黃煒燊
2024.371 A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) Prof. WONG Vincent Wai Sun
Vincent Wai Sun Wong
2017.163 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Prof. WONG Vincent Wai Sun
黃煒燊
2019.381 A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218 Alone or in Combination with Pegylated Interferon Alpha-2a Prof. WONG Vincent Wai Sun
2019.697 Effect of a Culturally Adapted Self-help Smartphone-based Lifestyle Intervention in Reducing Depressive Symptoms: A Randomized Controlled Trial Mr. WONG Vincent Wing Hei
黃穎僖
2021.369 Enhancing Group Lifestyle Intervention for Depression with Self-Tracking Tools: A Randomized Pilot Controlled Trial Mr. WONG Vincent Wing Hei
黃穎僖
2012.195 Laparoscopic total extraperitoneal inguinal hernia repair under spinal anaesthesia in patients who are unfit for general anaesthesia Dr. WONG Vivien Wai Yin
2015.008 Comparison of Outcome and Complications of Anterior versus Posterior Approach in Per-oral Endoscopic Myotomy (POEM) Procedure for Treatment of Achalasia: Randomized Single Blinded Clinical Trial Dr. WONG Vivien Wai Yin
2008.055 The Effectiveness of Hand-washing Program on Compliance with Hand Hygiene for Visiting Parents in Neonatal Unit Ms Wong Wai Fong
2017.330 An exploratory study on effects of self efficacy and interpersonal interaction on exercise adherence in Patients with chronic pain Mr. WONG Wai Lam
黃韋霖
2007.489 A Restrospective Study in Exploring the Effectiveness of ED Nurse-Initiated Asthma Protocol: Optimizing the Clinical Outcomes of Adult Asthma Patients Dr. WONG Wai Lin Marian
2021.179 The Effects of Multi-modal Intervention in Managing Symptom Cluster of Cancer-Related Fatigue-Sleeping Problem-Depressed Mood in Breast Cancer Patients undergoing Chemotherapy: A Randomized Controlled Trial Ms. WONG Wai Man
黃慧敏
2014.252 Investigation on the Treatment Effectiveness of Unloader One_ Knee Brace for Paitents with Knee Osteoarthritis Mr WONG Wai Man
2008.213 Validation of Magnetic Resonance Spectroscopy in Chinese Patients with Chronic Liver Diseases - A Cross Sectional Study with Histological Correlation Dr Wong Wai Sun
2010.232 Non-invasive diagnosis of liver firosis and cirrhosis in patients with nonalcoholic fatty liver disease with transient elastography (Fibroscan) and serum biomarkers Dr Wong Wai Sun

Page 231 of 254.